Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 17/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515284 | 0.91 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057125 | 0.91 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL11304197 | 0.91 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 0.91 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL10819300 | 0.91 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL24470621 | 0.84 | TLR2 (0.64) | TLR2LPAR1LPAR3 | |
| SCHEMBL24470523 | 0.84 | TLR2 (0.64) | TLR2LPAR1LPAR3 | |
| SCHEMBL28758973 | 0.84 | TLR2 (0.64) | TLR2LPAR1LPAR3 | |
| SCHEMBL14652628 | 0.84 | TLR2 (0.64) | TLR2LPAR1LPAR3 | |
| SCHEMBL15149390 | 0.84 | TLR2 (0.53) | TLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-03-08 | — | — | US | disclosed |
| US-7982027-B2 | silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell; hepatitis | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-07-19 | — | — | US | disclosed |
| US-20110091525-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091525-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | LIPA, PNLIP, PLTP | TLR2 845/4885LPAR1 65/4885LPAR3 88/4885 |
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | TLR2 2170/4885LPAR1 59/4885LPAR3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.